
Keywords: ADT; androgen-depletion therapy; AR; androgen receptor; BPH; benign prostatic hypertrophy; CAM-DR; cell adhesion-mediated drug resistance; CAM-RR; cell adhesion-mediated radiation resistance; CD49f; alpha-6 integrin sub-unit; CK; cytokeratin; CTC; circula